HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Online-Only Appendix All Versions of this Article: db07-0972v1 57/3/737    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Han, K. L. Articles by Hwang, J.-K. Search for Related Content PubMed PubMed Citation Articles by Han, K. L. Articles by Hwang, J.-K. Social Bookmarking                What's this?

Therapeutic Potential of Peroxisome Proliferators–Activated Receptor-/ Dual Agonist With Alleviation of Endoplasmic Reticulum Stress for the Treatment of Diabetes

¹ Department of Biotechnology, Yonsei University, Seodaemun-gu, Seoul, South Korea
² Division of Metabolic Disease, Department of Biomedical Science, National Institutes of Health, Seoul, South Korea
³ School of Oriental Medicine, Pusan National University, Busan, South Korea

Address correspondence and reprint requests to Prof. Myeong Ho Jung, School of Oriental Medicine, 30 Jangjeon-dong, Geumjeong-gu, Busan 609-735, South Korea. E-mail: jung0603{at}pusan.ac.kr; and Prof. Jae-Kwan Hwang, Department of Biotechnology, Yonsei University, Seodaemun-gu, Seoul 120-749, South Korea. E-mail: jkhwang{at}yonsei.ac.kr

Abbreviations: ACO, acyl-CoA oxidase; AMPK, AMP-activated protein kinase; aP2, adipose fatty acid–binding protein; CPT, carnitine palmitoyltransferase; ER, endoplasmic reticulum; FFA, free fatty acid; IB, inhibitor of B; IL, interleukin; IRS, insulin receptor substrate; JNK, c-Jun NH₂-terminal kinase; LPL, lipoprotein lipase; NF, nuclear factor; PPAR, peroxisome proliferators–activated receptor; PPRE, PPAR response element; TNF, tumor necrosis factor; UCP, uncoupling protein

OBJECTIVE—Peroxisome proliferator–activated receptor (PPAR) / dual agonists have the potential to be used as therapeutic agents for the treatment of type 2 diabetes. This study evaluated the function of macelignan, a natural compound isolated from Myristica fragrans, as a dual agonist for PPAR/ and investigated its antidiabetes effects in animal models.

RESEARCH DESIGN AND METHODS—GAL4/PPAR chimera transactivation was performed and the expression of PPAR/ target genes was monitored to examine the ability of macelignan to activate PPAR/. Additionally, macelignan was administrated to obese diabetic (db/db) mice to investigate antidiabetes effects and elucidate its molecular mechanisms.

RESULTS—Macelignan reduced serum glucose, insulin, triglycerides, free fatty acid levels, and triglycerides levels in the skeletal muscle and liver of db/db mice. Furthermore, macelignan significantly improved glucose and insulin tolerance in these mice, and without altering food intake, their body weights were slightly reduced while weights of troglitazone-treated mice increased. Macelignan increased adiponectin expression in adipose tissue and serum, whereas the expression and serum levels of tumor necrosis factor- and interleukin-6 decreased. Macelignan downregulated inflammatory gene expression in the liver and increased AMP-activated protein kinase activation in the skeletal muscle of db/db mice. Strikingly, macelignan reduced endoplasmic reticulum (ER) stress and c-Jun NH₂-terminal kinase activation in the liver and adipose tissue of db/db mice and subsequently increased insulin signaling.

CONCLUSIONS—Macelignan enhanced insulin sensitivity and improved lipid metabolic disorders by activating PPAR/ and attenuating ER stress, suggesting that it has potential as an antidiabetes agent for the treatment of type 2 diabetes.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?